

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of ANB033 - Part 1b

Submission date 10/07/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/09/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 08/04/2026	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

AnaptysBio, Inc. is developing the study treatment ANB033 as a potential new treatment for autoimmune and inflammatory diseases such as celiac disease (CeD). These diseases appear to be the result of an overreaction of a person's immune system which damages their own cells or organs.

ANB033 is an investigational monoclonal antibody, designed to reduce disease-causing immune cells and restore healthy immune balance. It is given by subcutaneous injection.

The purpose of this research study is to investigate ANB033 safety and tolerability when given to adult participants with CeD and how this treatment is absorbed and processed by the human body.

Who can participate?

Adults aged 18-70 years old with CeD

What does the study involve?

This study is testing the safety, tolerability of both single and multiple doses of a new experimental treatment called ANB033.

What are the possible benefits and risks of participating?

ANB033 is an experimental medication so the risks to human participants have not been fully evaluated.

The benefits, risks and side effects that may occur in participants treated with ANB033 are based on the results from nonclinical investigations of ANB033 and information available from the same class of compound effects.

Where is the study run from?

Australia, New Zealand and the Netherlands

When is the study starting and how long is it expected to run for?

October 2024 to March 2027

Who is funding the study?
AnaptysBio, Inc. (USA)

Who is the main contact?
clinicaltrialinfo@anaptysbio.com

Contact information

Type(s)
Public

Contact name
Dr Lewis Gryziewicz

Contact details
AnaptysBio, Inc.
10770 Wateridge Circle, Suite 210, CA
San Diego
United States of America
92121
+1 (0)4042746330
clinicaltrialinfo@anaptysbio.com

Type(s)
Scientific

Contact name
Dr Mark Rigby

Contact details
AnaptysBio, Inc.
10770 Wateridge Circle, Suite 210, CA
San Diego
United States of America
92121
+1 (0)4042746330
clinicaltrialinfo@anaptysbio.com

Type(s)
Principal investigator

Contact name
Dr Nah Yeon (Tina) Baik

Contact details
Level 2, 97 Grafton Road, Grafton
Grafton Auckland
New Zealand

1010
(+649) 303-4987
tina@optimalclinicaltrials.com

Type(s)

Principal investigator

Contact name

Dr Oscar Walsh

Contact details

Suite 9, 6/230 Blackshaws Road, VIC
Altona North
Australia
3025
+61 (0)1300903512
owalsh@altonaclinicalresearch.com

Additional identifiers

Clinical Trials Information System (CTIS)

2024-520409-38-00

Protocol serial number

ANB033-101

Study information

Scientific Title

A Phase I, randomized, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of ANB033 in adult participants - Part 1b

Study objectives

Part 1b of the study will comprise a multicenter, double-blind, randomized, placebo-controlled, parallel arm design that compares the safety and tolerability of multiple SC (subcutaneous) doses of ANB033 versus placebo in participants with celiac disease (CeD). Exploratory assessments of the effect of ANB033 on gastrointestinal (GI) symptoms and on intestinal histology will be conducted.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 21/01/2025, Bellberry Human Research Ethics Committee (123 Glen Osmond Road Eastwood, Adelaide, 5063, Australia; +61 (0)883613222; bellberry@bellberry.com.au), ref: 2024-11-1935

2. approved 25/03/2025, Southern Health and Disability Ethics Committee (Ministry of Health, PO Box 5013, Wellington, 6140, New Zealand; +64 (0)800 855 066; hdec@health.govt.nz), ref: 2025 FULL 21884

Study design

Multicenter double-blind randomized placebo-controlled parallel-arm trial

Primary study design

Interventional

Study type(s)

Safety, Other

Health condition(s) or problem(s) studied

Celiac disease

Interventions

Part 1b of the study will comprise a multicenter, double-blind, randomized, placebo-controlled, parallel arm design that compares the safety and tolerability of a single SC (subcutaneous) dose level of ANB033 or placebo in participants with CeD. Part 1b will enroll adults with CeD every 2 weeks for a total of three doses. Part 1b of the study will enroll adults with CeD.

Participants will be randomized to subcutaneous ANB033 or placebo in a 1:1 ratio.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

ANB033

Primary outcome(s)

The safety and tolerability of ANB033 in participants with celiac disease:

1. Incidence, type, and severity of all adverse events (AEs) recorded at Days 1, 15, 29, 36, 43, 57, 71, 85, 99, 127, 155, and 183
2. Vital signs, ECGs, physical examinations, and clinical laboratory assessments measured at Days 1, 15, 29, 36, 43, 57, 71, 85, 99, 127, 155, and 183

Key secondary outcome(s)

1. Pharmacokinetic (PK) parameters measured using a fully validated ligand-binding assay and noncompartmental analysis at Days 1, 15, 29, 36, 43, 57, 85, 99, 127
2. Incidence of confirmed positive anti-drug antibodies (ADAs) and titers measured using a fully validated ligand-binding assay at Days, 1, 15, 29, 36, 43, 57, 71, 85, 127

Completion date

09/03/2027

Eligibility

Key inclusion criteria

1. Male or female aged 18 to 70 years old
2. Willing and able to provide informed consent
3. Female participants must not be pregnant or lactating
4. Male participants must be willing to comply with protocol contraceptive requirements
5. Have an established diagnosis of celiac disease, including diagnostic findings from a duodenal biopsy AND have had this diagnosis at least 12 months prior to Screening
6. Adhered to a gluten-free diet and willing to comply with a gluten-free diet
7. Willing to comply with necessary tests and protocol requirements

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

70 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Has signs, symptoms, or current diagnosis of concerning, severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, GI, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances.
2. Participant has a BMI of <16 or >35 kg/m² or total body weight <45 kg (99 lb) (Note: BMI = weight (kg)/[height (m)]²).
3. Participant smokes cigarettes or has quit smoking within 3 months of screening.
4. History of clinically significant drug or alcohol abuse
5. Clinically significant, abnormal 12-lead ECG
6. Planned surgery within 4 months prior to the start of screening
7. History of drug allergy, suspected medical condition, including autoimmune or inflammatory conditions, that currently requires or may require systemic immunomodulatory or immune suppressive therapy.
8. Predisposed to develop an infection
9. Positive for hepatitis B, hepatitis C and HIV-1 or HIV-2 antibodies
10. Diagnosis of, suspected diagnosis of, or concerns of acquiring active TB or currently with untreated latent TB.

Date of first enrolment

20/10/2025

Date of final enrolment

31/07/2026

Locations**Countries of recruitment**

Australia

Netherlands

New Zealand

Study participating centre**Site 1**

Altona North

Altona North

Australia

3025

Study participating centre**Site 2**

Taringa

Taringa

Australia

4068

Study participating centre**Site 3**

Auckland

Auckland

New Zealand

1010

Study participating centre**Site 4**

Waikanae Beach

Waikanae Beach

New Zealand

5036

Study participating centre

Site 5

Auckland
Auckland
New Zealand
0622

Study participating centre

Site 6

Wellington
Wellington
New Zealand
5010

Study participating centre

Site 7

Arnhem
Arnhem
Netherlands
6815 AD

Study participating centre

Site 8

Amsterdam
Amsterdam
Netherlands
1081 HV

Study participating centre

Site 9

Christchurch
New Zealand
8011

Sponsor information

Organisation

AnaptysBio, Inc.

Funder(s)

Funder type

Industry

Funder Name

AnaptysBio, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available